Profound Medical Corp. is a medical technology company. It is focused on a therapeutics platform which provides the precision of real-time Magnetic Resonance Imaging technology for the incision-free ablation of diseased tissue. The company principally commercialized the TULSA-PRO(R) and Sonalleve(R) platforms. Profound Medical Corp. is based in Mississauga, Canada.
Revenue (Most Recent Fiscal Year) | $7.20M |
Net Income (Most Recent Fiscal Year) | $-28.57M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 30.57 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.83 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -388.52% |
Net Margin (Trailing 12 Months) | -386.63% |
Return on Equity (Trailing 12 Months) | -70.08% |
Return on Assets (Trailing 12 Months) | -53.76% |
Current Ratio (Most Recent Fiscal Quarter) | 5.41 |
Quick Ratio (Most Recent Fiscal Quarter) | 4.73 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | 0.38 |
Book Value per Share (Most Recent Fiscal Quarter) | $1.28 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.26 |
Earnings per Share (Most Recent Fiscal Year) | $-1.35 |
Diluted Earnings per Share (Trailing 12 Months) | $-1.29 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Medical Devices |
Common Shares Outstanding | 24.43M |
Free Float | 24.06M |
Market Capitalization | $221.57M |
Average Volume (Last 20 Days) | 0.03M |
Beta (Past 60 Months) | 0.82 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 1.52% |
Percentage Held By Institutions (Latest 13F Reports) | 47.86% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |